To cite this article: Klok FA, Dzikowska-Diduch O, Kostrubiec M, Vliegen HW, Pruszczyk P, Hasenfuß G, Huisman MV, Konstantinides S, Lankeit M. Derivation of a clinical prediction score for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism.J Thromb Haemost 2016; 14: 121-8.
Essentials• Predicting chronic thromboembolic pulmonary hypertension (CTEPH) after pulmonary embolism is hard.• We studied 772 patients with pulmonary embolism who were followed for CTEPH (incidence 2.8%).• Logistic regression analysis revealed 7 easily collectable clinical variables that combined predict CTEPH.• Our score identifies patients at low (0.38%) or higher (10%) risk of CTEPH.Summary. Introduction: Validated risk factors for the diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH) after acute pulmonary embolism (PE) are currently lacking. Methods: This is a post hoc patient-level analysis of three large prospective cohorts with a total of 772 consecutive patients with acute PE, without major cardiopulmonary or malignant comorbidities. All underwent echocardiography after a median of 1.5 years. In cases with signs of pulmonary hypertension, additional diagnostic tests to confirm CTEPH were performed. Baseline demographics and clinical characteristics of the acute PE event were included in a multivariable regression analysis. Independent predictors were combined in a clinical prediction score. Results:CTEPH was confirmed in 22 patients (2.8%) by right heart catheterization. Unprovoked PE, known hypothyroidism, symptom onset > 2 weeks before PE diagnosis, right ventricular dysfunction on computed tomography or echocardiography, known diabetes mellitus and thrombolytic therapy or embolectomy were independently associated with a CTEPH diagnosis during follow-up. The area under the receiver operating charateristic curve (AUC) of the prediction score including those six variables was 0.89 (95% confidence interval [CI] 0.84-0.94). Sensitivity analysis and bootstrap internal validation confirmed this AUC. Seventy-three per cent of patients were in the low-risk category (CTEPH incidence of 0.38%, 95% CI 0-1.5%) and 27% were in the high-risk category (CTEPH incidence of 10%, 95% CI 6.5-15%). Conclusion: The 'CTEPH prediction score' allows for the identification of PE patients with a high risk of CTEPH diagnosis after PE. If externally validated, the score may guide targeting of CTEPH screening to at-risk patients.
TAPSE is preferable to the RV/LV ratio for risk stratification in initially normotensive patients with APE. TAPSE ≤15 mm identifies patients with an increased risk of 30-day APE-related mortality, whereas TAPSE >20 mm can be used for identification of a very low-risk group.
Background
The current diagnostic delay of chronic thromboembolic pulmonary
hypertension (CTEPH) after pulmonary embolism (PE) is unacceptably long,
causing loss of quality-adjusted life years and excess mortality.
Validated screening strategies for early CTEPH diagnosis are lacking.
Echocardiographic screening among all PE survivors is associated with
overdiagnosis and cost-ineffectiveness. We aimed to validate a simple
screening strategy for excluding CTEPH early after acute PE, limiting
the number of performed echocardiograms.
Methods
In this prospective, international, multicentre management study,
consecutive patients were managed according to a screening algorithm
starting 3 months after acute PE to determine whether echocardiographic
evaluation of pulmonary hypertension (PH) was indicated. If the ‘CTEPH
prediction score’ indicated high pretest probability or matching
symptoms were present, the ‘CTEPH rule-out criteria’ were applied,
consisting of ECG reading and N-terminalpro-brain natriuretic peptide.
Only if these results could not rule out possible PH, the patients were
referred for echocardiography.
Results
424 patients were included. Based on the algorithm, CTEPH was
considered absent in 343 (81%) patients, leaving 81 patients (19%)
referred for echocardiography. During 2-year follow-up, one patient in
whom echocardiography was deemed unnecessary by the algorithm was
diagnosed with CTEPH, reflecting an algorithm failure rate of 0.29% (95%
CI 0% to 1.6%). Overall CTEPH incidence was 3.1% (13/424), of whom 10
patients were diagnosed within 4 months after the PE
presentation.
Conclusions
The InShape II algorithm accurately excluded CTEPH, without the need
for echocardiography in the overall majority of patients. CTEPH was
identified early after acute PE, resulting in a substantially shorter
diagnostic delay than in current practice.
Acute kidney injury assessed by N-GAL occurs in 30% of APE and may contribute to the impairment of renal function present in half of them. Moreover, N-GAL, cystatin C elevation and low eGFR are associated with a poor 30-day prognosis in APE.
Background: Significant achievements in the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) have provided effective therapeutic options for most patients. However, the true impact of the changed landscape of CTEPH therapies on patients’ management and outcomes is poorly known. We aimed to characterize the incidence, clinical characteristics, and outcomes of CTEPH patients in the modern era of CTEPH therapies. Methods: We analyzed the data of CTEPH adults enrolled in the prospective multicenter registry. Results: We enrolled 516 patients aged 63.8 ± 15.4 years. The incidence rate of CTEPH was 3.96 per million adults per year. The group was burdened with several comorbidities. New oral anticoagulants ( n = 301; 58.3%) were preferred over vitamin K antagonists ( n = 159; 30.8%). Pulmonary endarterectomy (PEA) was performed in 120 (23.3%) patients and balloon pulmonary angioplasty (BPA) in 258 (50%) patients. PEA was pretreated with targeted pharmacotherapy in 19 (15.8%) patients, and BPA in 124 (48.1%) patients. Persistent CTEPH was present in 46% of PEA patients and in 65% of patients after completion of BPA. Persistent CTEPH after PEA was treated with targeted pharmacotherapy in 72% and with BPA in 27.7% of patients. At a mean time period of 14.3 ± 5.8 months, 26 patients had died. The use of PEA or BPA was associated with better survival than the use of solely medical treatment. Conclusions: The modern population of CTEPH patients comprises mostly elderly people significantly burdened with comorbid conditions. This calls for treatment decisions that are tailored individually for every patient. The combination of two or three methods is currently a frequent approach in the treatment of CTEPH. Clinical Trial Registration: clinicaltrials.gov/ct2/show/NCT03959748
which is estimated at more than 15%. 4,5 Fortunately most APE patients are hemodynamically stable at admission but the early mortality risk is different in this population. Risk stratification of non-high-risk APE patients is based on clinical presentation, cardiac laboratory biomarkers, and signs of right ventricular (RV) dysfunction on echocardiography or computed tomography. 4,6 Low-risk patients require a short hospital stay and can be early discharged home or even treated as outpatients. 7 Intermediate-risk subjects comprise a very heterogeneous group in which the early mortality ranges between 2% and 15%. 4 More of A cute pulmonary embolism (APE) is the most serious clinical presentation of venous thromboembolism (VTE). According to registries and hospital discharge databases of unselected patients with APE and VTE, 30-day all-cause mortality rates are between 9% and 10%. 1-3 According to the recent European Society of Cardiology (ESC) guidelines on the diagnosis and treatment of APE patients, clinical classification of the severity of an episode of APE is based on the estimated 30-day APErelated mortality risk. 4 Patients with cardiogenic shock caused by APE comprise a high-risk group for early death, Background: Patients with intermediate-risk acute pulmonary embolism (APE) are a heterogeneous group with an early mortality rate of 2-15%. The tricuspid annulus plane systolic excursion (TAPSE) and tricuspid regurgitation peak gradient (TRPG) can be used for risk stratification, so we analyzed the prognostic value of a new echo parameter (TRPG/TAPSE) for prediction of APE-related 30-day death or need for rescue thrombolysis in initially normotensive APE patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.